Viatris Inc. which can be found using ticker (VTRS) have now 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 35 and 10 suggesting an average Analsyt target price of $14.45. Given that the stocks previous close was at $9.35 and the analysts are correct then we can expect a percentage increase in value of 54.5%. There is a 50 day moving average of $9.51 and the 200 day MA is $10.35. The market capitalization for the company is 11.08B. The current stock price for Targa Resources Corp. is currently 9.24 USD
The potential market cap would be $17,122,147,980 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 5.89, revenue per share of 13.06 and a 3.05% return on assets.
Viatris Inc. is a global healthcare company. The Company’s segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company’s ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands, complex generics, and biosimilars. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.
